Analysis of what diseases and indications Tazetostat (Davico) mainly treats

Tazemetostat (Tazemetostat) is a selective EZH2 (enhancer homolog 2) inhibitors change the epigenetic status of tumor cells by blocking the activity of EZH2, an epigenetic regulatory enzyme, thereby inhibiting the growth and survival of cancer cells. EZH2It is highly expressed or has gene mutations in some malignant tumors, which promotes the occurrence and development of tumors. Therefore, tazerestat shows unique therapeutic advantages in this type of tumors.

Clinically, the main indication for tazerestat is relapsed or refractory follicular lymphoma (FL), especially for patients with EZH2 mutations. Studies have shown that such patients have a higher response rate to tazerestat, and their progression-free survival (PFS) is significantly prolonged. In addition, even patients with EZH2 wild-type follicular lymphoma have certain therapeutic benefits, so this drug has become one of the important treatment options for patients with follicular lymphoma, especially after failure of multiple lines of treatment.

In addition to follicular lymphoma, tazerestat is also approved for advanced or metastatic epithelioid sarcoma (epithelioid sarcoma). This is a rare and highly aggressive soft tissue tumor that commonly occurs in young adults and has very limited treatment options. The application of tazerestat provides new hope for such patients, and clinical studies have shown that the drug can partially shrink tumors or delay disease progression. The approval of tazerestat is landmark because of the small population of patients with epithelioid sarcoma.

In summary, the indications for tazerestat mainly include EZH2 mutated follicular lymphoma, some EZH2 wild-type follicular lymphoma patients, and advanced or metastatic epithelioid sarcoma. As research deepens, the drug is also exploring the possibility of being used in other malignant tumors, such as diffuse large BB cell lymphoma (DLBCL), ovarian cancer, etc. At present, tazerestat has become an important targeted drug for specific patient groups, especially in the treatment of relapsed or refractory tumors, and has played an important clinical value.

Reference materials:https://www.drugs.com/